secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2023-09-05T23:59:59+00:00
Accession:  0001628280-23-031405
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma submits NDA to FDA for mavorixafor in WHIM syndrome
-------------------------------------------------------------

- Submission supported by positive Phase 3 4WHIM trial results; met primary and key secondary endpoints.
- Requested priority review; if granted, FDA review period would be six months from acceptance.
- Mavorixafor is an oral once-daily candidate for WHIM syndrome, a rare primary immunodeficiency in patients 12+.
- No treatment-related serious adverse events or discontinuations for safety in the Phase 3 trial.
- CEO Paula Ragan calls it a significant milestone; could be first approved U.S. product for WHIM syndrome.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023031405/0001628280-23-031405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828023031405/xfor-20230905.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-031405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer